Advances in Pharma Business Management and Research : (Record no. 305614)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04959nam a22004333i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC6122108 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240122001209.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 231124s2020 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9783030359188 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9783030359171 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC6122108 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL6122108 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1143625864 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RS400-431 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Schweizer, Lars. |
| 245 10 - TITLE STATEMENT | |
| Title | Advances in Pharma Business Management and Research : |
| Remainder of title | Volume 1. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Cham : |
| Name of producer, publisher, distributor, manufacturer | Springer International Publishing AG, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2020. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | �2020. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (93 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- Preface -- Contents -- About the Editors -- Introduction: Trends and Developments in the Pharmaceutical and Life Sciences Industry -- Relevance of Instruments for Measurements of Quality of Life in the AMNOG Context: An Analysis of the Endpoint Health-Related ... -- 1 Relevance of Instruments for Measurements of Quality of Life in the AMNOG Context -- 1.1 An Analysis of the Endpoint Health-Related Quality of Life from Different Perspectives -- 2 Methods -- 3 Results and Conclusions -- 4 Outlook -- References -- Quality Management System for RandD Project and Portfolio Management in Pharmaceutical Company -- 1 Introduction -- 2 Theoretical Background -- 2.1 Theories -- 2.2 Pharmaceutical Project Management Quality System Model -- 2.3 Hypotheses -- 3 Empirical Analysis -- 3.1 Methodology -- 3.1.1 Characterization of PPMQS Enabling and Result Systems -- 3.2 Testing of Hypotheses -- 4 Empirical Findings -- 4.1 Characterization of Enabling and Result Systems -- 4.2 Testing of Hypotheses -- 5 Discussion -- References -- Brexit and Its Impact on Pharmaceutical Law: Implications for Global Pharma Companies -- 1 Brexit Scenarios -- 2 Impact on the Drug Regulatory Framework -- 3 Recommended Actions for Companies -- 4 Conclusions and Outlook -- References -- Implementation of Measurable and Sustainable Actions to Improve Employee�s Engagement and Business Performance: Global Medical... -- 1 Background -- 2 Statement of Expectations -- 2.1 With Onboarding the Bond of Employees to the Company will be Increased -- 2.2 Regular Feedback Meetings with Superiors will Engage Employees -- 2.3 Personal Development Plans will Lead to Better Performance -- 3 Managerial Implications -- 3.1 Implications on Fresenius Kabi -- 4 Direction for Future Research -- 5 Conclusion -- References. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Leadership Models and Work Behavior: An Empirical Analysis of Consequences of Authentic and Transformational Leadership -- 1 The Importance of Leadership for Corporate Success -- 2 The Concept of Leadership -- 3 Constructs and Generation of Hypotheses -- 4 Empirical Assessment of the Models -- 5 Summary, Implications and Outlook -- References -- Alliance Management at Merck: Establishing an Operational 100-Day Plan for Alliance Launches and Management -- 1 Introduction -- 2 The Importance of Alliances for the Pharmaceutical Industry -- 2.1 The Problem ``Productivity Paradox�� -- 2.2 Cooperation as a Potential Solution -- 3 The Nature of Alliances -- 3.1 Definitions and Types of Alliances -- 3.2 The Lifecycle of Alliances -- 3.3 The Role of the Alliance Management -- 4 Merck KGaA and Its Alliances -- 4.1 History of Merck KGaA -- 4.2 Significant Biopharma Alliances of Merck -- 4.3 Alliance Management at Merck -- 5 The Operational 100-Day Plan -- 6 The Online Survey on the 100-Day Plan -- 6.1 General Statistics -- 6.2 Alliance Launch Phase -- 6.3 Governance of Alliances -- 6.4 Evaluation of Alliances -- 6.5 Feedback on the 100-Day Plan -- 7 Conclusion and Outlook -- Appendix 1: Operational 100-Day Plan for Alliance Launch -- References -- Correction to: Introduction: Trends and Developments in the Pharmaceutical and Life Sciences Industry -- Correction to: Chapter 1 in: L. Schweizer et al. (eds.), Advances in Pharma Business Management and Research, https://doi.org/. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2023. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dingermann, Theodor. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Russe, Otto Quintus. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Jansen, Christian. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Schweizer, Lars |
| Title | Advances in Pharma Business Management and Research |
| Place, publisher, and date of publication | Cham : Springer International Publishing AG,c2020 |
| International Standard Book Number | 9783030359171 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/bacm-ebooks/detail.action?docID=6122108">https://ebookcentral.proquest.com/lib/bacm-ebooks/detail.action?docID=6122108</a> |
| Public note | Click to View |
No items available.